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Introduction
Osteoporosis is a disease characterized by reduced bone mass 
and strength. Adult bone is continuously remodeled by osteoclas-
tic bone resorption and osteoblastic bone formation. Advances 
in the treatment of osteoporosis have made substantial improve-
ment in the management of patients with osteoporosis and the 
prevention of osteoporotic fractures. Many of these drugs increase 
bone mass and strength by inhibiting bone resorption, but there 
are drugs that increase bone formation. In this review, we sum-
marize recent advances in the development of anti-osteoporotic 
drugs by focusing on bisphosphonates, denosumab, teriparatide, 
abaloparatide, and romosozumab. There are other drugs being used 
for the treatment of osteoporosis in some areas of the world but 
not discussed in this review, such as selective estrogen receptor 
modulators, active vitamin D compounds, vitamin K compound, 
strontium ranelate, calcitonin, and parathyroid hormone (PTH) 
(1–84).
Bisphosphonates
The first bisphosphonate developed for the treatment of oste-
oporosis was etidronate, which had weak anti-resorptive activity 
compared with its mineralization inhibitory activity. Thereafter, 
nitrogen-containing bisphosphonates with much stronger anti-
resorptive activity have become the main drugs for patients with 
osteoporosis. Bisphosphonates bind to hydroxyapatite during 
mineralization or demineralization and are released under 
acidic condition during osteoclastic bone resorption. Nitrogen- 
containing bisphosphonates suppress bone resorption by inhib-
iting the activities of osteoclasts and inducing their apoptosis. 
These drugs mainly increase the bone mineral density (BMD) of 
trabecular bones. For example, it has been shown that alendronate 
increased lumbar BMD for up to 10 years1. In contrast, the increase 
of BMD in proximal femur or total body reached a plateau after 
3 to 5 years1. Similarly, the increase of proximal femoral BMD 
by once-yearly intravenous administration of zoledronic acid 
was evident for up to 4 years2. However, femoral BMD remained 
stable after that period, even with continuing administration of 
zoledronic acid. In addition, phase 3 clinical trials have shown that 
several nitrogen-containing bisphosphonates prevent vertebral, 
non-vertebral, and proximal femoral fractures during treatment 
for 3 years. However, the effects of long-term administration of 
nitrogen-containing bisphosphonates on fracture prevention, 
especially of non-vertebral bones, are not clear. In a study com-
paring the effects of continuous administration of alendronate for 
10 years and alendronate for 5 years followed by placebo for 
5 years, clinical vertebral fractures were reduced in patients who 
received alendronate for 10 years3. However, there was no dif-
ference in the frequency of morphometric vertebral fractures, 
non-vertebral fractures, proximal femoral fractures, and wrist frac-
tures between patients who received alendronate for 10 years and 
5 years3. Similarly, there was no difference in the frequency of 
morphometric vertebral fractures and clinical fractures in patients 
who received intravenous zoledronic acid for 9 years and 6 years 
followed by placebo for 3 years2, although fracture risk remained 
lower in the patients receiving zoledronic acid compared with 
those without zoledronic acid treatment. These results suggest that 
the efficacy of bisphosphonate on fracture prevention reaches a 
plateau after several years.
In addition to bisphosphonates’ plateauing efficacy, their long-
term use has been shown to be associated with atypical femoral 
fractures (AFFs)4. Large doses of intravenous bisphosphonates 
for the treatment of cancer-associated bone diseases are associ-
ated with an increased risk of osteonecrosis of the jaw (ONJ). The 
incidence of ONJ in subjects whose osteoporosis was treated with 
low doses of oral or intravenous bisphosphonates is very low, 
and there is a report suggesting that the incidence of ONJ is not 
increased among patients whose osteoporosis was treated with 
bisphosphonate5. Because of these adverse events, a drug holiday 
is proposed for some patients receiving bisphosphonates6. From 
those results, it is clear that there are several limitations for 
nitrogen-containing bisphosphonates, although they certainly 
increase BMD and prevent fractures, especially during the first 
several years.
The anti-resorptive activity of bisphosphonates is determined 
by the balance among several processes, and the behavior of each 
bisphosphonate is quite different. These include (a) binding of 
bisphosphonates in the circulation to the mineralized surface of 
bone matrix, (b) release from the bone surface under an acidic 
environment by osteoclastic bone resorption, and (c) inhibition of 
farnesyl pyrophosphate synthase (FPPS) after being taken up by 
osteoclasts7. FPPS is a rate-limiting enzyme for the formation of 
geranylgeranyl pyrophosphate, which prenylates and activates 
small GTP-binding proteins such as Rab, Rho, and Rac, and 
inhibition of FPPS leads to the suppression of osteoclastic bone 
resorption. Thus, if the affinity of a bisphosphonate for the 
mineralized surface of bone under the circulating blood pH is low, 
only an insufficient amount of bisphosphonate could be accu-
mulated on the bone surface. Alternatively, even though a low 
amount of bisphosphonate is accumulated on the bone surface, if 
the affinity of bisphosphonate is low at the Howship’s lacunae under 
an acidic environment, enough bisphosphonate could be released 
and taken up by osteoclasts. If a similar amount of bisphospho-
nate is taken up by osteoclasts, the anti-resorptive activity of 
bisphosphonate would be determined by the affinity and inhibitory 
activity of that bisphosphonate for FPPS.
On the mineralized bone surface, hydroxyapatite crystal is bound 
to collagen matrix, and the affinity of bisphosphonate for the 
bone surface is determined by its affinity for hydroxyapatite. The 
affinity for hydroxyapatite at neutral pH is highest for zoledronic 
acid, followed by alendronate and minodronate, and is lowest for 
risedronate followed by ibandronate. Under acidic pH, the affin-
ity for hydroxyapatite is highest for alendronate, followed by 
zoledronic acid and risedronate, and is lowest for minodronate8. 
Given the long-term accumulation of bisphosphonate in bone, the 
ideal property of bisphosphonate would be low affinity at neutral 
pH with less accumulation on the bone surface but low affinity at 
acidic pH with enough bisphosphonate to be released from bone 
and strong inhibitory activity to FPPS with inhibition of osteoclas-
tic bone resorption9. Most long-term adverse events such as AFF 
were reported using alendronate or zoledronic acid, which have 
high affinity to mineralized bone at neutral and acidic pH, but 
there are bisphosphonates such as minodronate and risedronate 
that have physico-chemical characteristics that are substantially 
different from those of alendronate or zoledronic acid. Therefore, 
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we have to take into consideration that the long-term efficacy on 
vertebral and non-vertebral fractures, as well as safety issues such 
as ONJ and AFF, may be different among bisphosphonates with 
different pharmacological and physico-chemical characteristics.
Denosumab
Receptor activator of nuclear factor-kappa B ligand (RANKL) 
expressed in osteoblastic cells binds to its receptor, RANK, on 
the surface of osteoclasts and their precursor cells. The binding 
of RANKL to RANK is essential for osteoclast formation, 
activity, and survival. Denosumab is a human monoclonal anti-
body against RANKL and has been used for patients with oste-
oporosis, bone metastases, multiple myeloma, and giant cell tumor 
of bone. The pivotal phase 3 clinical trial Fracture REduction 
Evaluation of Denosumab in Osteoporosis every 6 Months 
(FREEDOM) in postmenopausal women with osteoporosis indi-
cated that denosumab prevented vertebral, non-vertebral, and hip 
fractures10. There was a close relationship between femoral neck 
BMD change and fracture risk reduction11. Denosumab showed 
long-term continuous effects on lumbar and proximal femoral 
BMD and on vertebral and non-vertebral fracture prevention for 
up to 10 years12,13. Denosumab also increased BMD of 1/3 radius 
consisting of mainly cortical bone almost in a linear fashion. This 
continuous increase of radial BMD was not reported in patients 
receiving oral bisphosphonates14. These results demonstrate that 
denosumab has potent effects on not only trabecular bone but also 
cortical bone, effects that were not observed using bisphosphonates. 
Long-term use of denosumab also has anti-fracture effects different 
from those of bisphosphonates. The yearly incidence of non-ver-
tebral fractures was lower in patients who continued denosumab 
in the FREEDOM extension study. Whereas the annual incidence 
of non-vertebral fractures was more than 2% in the first 3 years 
of denosumab treatment in the FREEDOM study, it became less 
than 2% during 4 to 7 years of denosumab treatment and 0.7% in 
year 813. These results are consistent with the assumption that the 
prevention of non-vertebral fractures by denosumab becomes more 
prominent with long-term use of denosumab. However, it should be 
noted that a randomized controlled trial was performed for 3 years 
in the FREEDOM study, and there were no placebo controls in the 
extension study.
The clearance of denosumab from the blood circulation is very 
slow because it is not excreted from the kidney or metabolized 
in the liver but is cleared by the reticuloendothelial system. 
Consistent with the gradual decrease in the circulating denosumab 
concentration, bone resorption markers start to increase 4 months 
after denosumab injection and keep increasing toward the next 
injection at 6 months15. RANKL expression by osteoblasts and 
osteocytes is expected to increase at sites of bone with microc-
racks or deteriorated strength. Thus, there is a possibility that after 
4 to 6 months of denosumab injection, bone remodeling can 
take place, especially where RANKL expression is high. Such a 
possibility needs to be tested in the future.
Because denosumab rapidly inhibits RANKL-induced bone 
resorption, if patients do not receive enough vitamin D or calcium 
or both, there is a risk of hypocalcemia, especially during the 
first week after administration. Denosumab is also reported to be 
associated with an increased risk of AFF and ONJ. The non- 
accumulating, reversible nature of the action of denosumab also 
causes a rapid increase in bone turnover after discontinuation, 
resulting in a rapid loss of bone and a possible increase in 
fractures16. Thus, treatment with other anti-resorptive drugs is 
required after discontinuation of denosumab. It should also be 
noted that switching to teriparatide after denosumab treatment 
further enhances bone remodeling and causes a temporal reduc-
tion in vertebral and proximal femoral BMD and a more prolonged 
reduction in radial BMD17.
Teriparatide
Teriparatide is a peptide corresponding to the 34 N-terminal 
amino acids of PTH. Daily subcutaneous injections of teriparatide 
were shown to increase lumbar BMD and prevent vertebral 
and non-vertebral fractures18. Teriparatide treatment markedly 
increases trabecular bone mass but is associated with bone loss at 
sites composed of mainly cortical bone, such as distal radius. After 
several months of teriparatide treatment, teriparatide stimulates 
bone resorption by increasing bone remodeling18. This enhanced 
bone resorption causes reduced bone mass and increased cortical 
porosity in peripheral bones19. The use of teriparatide is limited to 
2 years in any life span, and this is because of the development 
of osteosarcoma in pre-clinical animal studies and the decrease 
of effects to increase BMD. Because long-term teriparatide use 
is currently not possible, it is necessary to gain maximal benefit 
of teriparatide during the 2 years. Previous studies indicated that 
a combination of alendronate with teriparatide does not have an 
overall superior effect on BMD20,21. The combination of zoledronic 
acid and teriparatide induced faster gain in lumbar and hip BMD 
than the respective drug alone until 26 weeks. After 52 weeks, lum-
bar BMD in the teriparatide group and hip BMD in the zoledronic 
acid group were similar to those in the combination group22. 
In contrast, the recent Denosumab and Teriparatide Administra-
tion (DATA) study indicated that the combination of denosumab 
and teriparatide produced a more prominent effect on BMD than 
each drug did alone23,24. The combination of teriparatide and 
denosumab may have the strongest anti-fracture efficacy among 
currently available regimens. As mentioned earlier, the DATA-
Switch study indicated that teriparatide treatment after denosumab 
was associated with transient bone loss in lumbar spine and proxi-
mal femur and with prolonged BMD decrease in distal radius17. 
In contrast, teriparatide followed by denosumab continuously 
increased the BMD of lumbar spine and proximal femur. Thus, it is 
necessary to consider the timing of teriparatide use, as well as the 
order of sequential use of teriparatide, in the long-term manage-
ment of patients with osteoporosis.
Abaloparatide
Abaloparatide is a synthetic analog of the 34 N-terminal amino 
acid region of PTH-related protein (PTHrP) with substitution of 
eight amino acids from amino acid 22 to 31 and Ala34 to Ala-NH
2
. 
PTH and PTHrP bind to the same PTH1 receptor through their N- 
terminal portions. PTHR1 can take two conformations, R(0) and 
RG; R(0) binding results in prolonged signaling, whereas RG bind-
ing causes more transient responses. Abaloparatide binds more 
preferably to the RG conformation and is shown to cause a more 
transient response than does teriparatide25. The more transient 
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action of abaloparatide via binding to the RG conformation of 
PTHR1 appears to favor the anabolic effect of abaloparatide with 
fewer bone resorptive effects. Because abaloparatide is currently 
under development, most of its clinical data come from a phase 3 
clinical study (Abaloparatide Comparator Trial in Vertebral End-
points [ACTIVE]). In that study, abaloparatide was shown to 
increase BMD and reduce vertebral and non-vertebral fractures 
in postmenopausal women with osteoporosis over 18 months26. 
The reduction of non-vertebral fractures by abaloparatide was 
significant when compared with placebo, but there was no 
difference in non-vertebral fractures between the teriparatide 
and placebo groups. The effects of abaloparatide on the increase 
in BMD of lumbar spine and proximal femur were shown to be 
greater than those of teriparatide. Hypercalcemia was lower in 
the abaloparatide than the teriparatide group26. The superior anti- 
fracture effects, especially on non-vertebral fractures with less 
hypercalcemic effect, may render abaloparatide a safe and effective 
anabolic agent when approved for the treatment of osteoporosis.
Romosozumab
Canonical Wnt signaling plays a pivotal role in maintaining 
bone homeostasis. Mouse and human genetic data indicate that 
canonical Wnt–β-catenin signaling enhances osteoblastic bone 
formation and inhibits bone resorption via direct and indirect 
mechanisms. Enhanced Wnt–β-catenin signaling in osteoblas-
tic lineages increases bone mass, whereas reduced signaling 
decreases bone mass27. Although Wnt signaling ubiquitously 
affects almost all types of cells, Wnt–β-catenin signaling in bone 
is controlled by sclerostin, a glycoprotein selectively secreted 
from osteocytes. Sclerostin is an inhibitor of Wnt signaling and 
potently inhibits bone formation. Romosozumab is a humanized 
monoclonal antibody against sclerostin. Romosozumab is also 
under clinical development, and a phase 3 study demonstrated 
that romosozumab was shown to markedly increase the BMD of 
lumbar spine by 13.3% and proximal femur by 6.8% in just 
12 months and prevent vertebral and clinical fractures in post-
menopausal women with osteoporosis28. Although non-vertebral 
fractures were not significantly reduced by 12-month romoso-
zumab treatment, the low rate of non-vertebral fracture in the 
placebo group among the Latin American participants might have 
affected these results. In a post hoc analysis including only 
subjects outside Latin America, there was a significant 42% 
reduction in non-vertebral fractures in 1 year because of the 
higher incidence of non-vertebral fractures in the placebo group 
(2.7%)28. Among bone turnover markers, a bone formation 
marker, PINP, increased rapidly 14 days after the first injection 
and gradually decreased to baseline by 9 months, and there was a 
transient increase after repeated romosozumab injections28. A bone 
resorption marker, β-CTX, decreased rapidly on day 14 after the 
first injection and remained suppressed for 12 months28. Thus, 
romosozumab increased bone formation and suppressed bone 
resorption. It must be emphasized that this therapeutic profile is 
unique to romosozumab. Given the robust anti-fracture effect after 
only 12 months of treatment, romosozumab can become a strong 
therapeutic option for the treatment of osteoporosis.
Conclusions
There are differences in the duration of anti-fracture effect among 
the currently available anti-resorptive agents. It is important to 
analyze the difference in the mode of action, efficacy in fracture 
prevention, and safety profiles of these agents in order to develop 
safe and effective management of patients with osteoporosis. After 
the report on ONJ and AFFs among bisphosphonate and deno-
sumab users, there has been increasing concern about the use of 
drugs for osteoporosis treatment. The current crisis of osteoporosis 
treatment, owing to the reduction in the number of patients under 
treatment and the increase in hip fractures, can be overcome by 
these efforts29. The development of new bone-forming agents such 
as abaloparatide and romosozumab will increase treatment choice 
in patients with various severities of osteoporosis and will facilitate 
the understanding of the necessity and rationale for the combined or 
sequential treatment of osteoporosis.
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